Literature DB >> 29667112

Migraine Therapy: Current Approaches and New Horizons.

Peter J Goadsby1,2, Philip R Holland3.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29667112      PMCID： PMC5935654          DOI： 10.1007/s13311-018-0626-3

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN： 1878-7479            Impact factor:   7.620


× No keyword cloud information.
  41 in total

Review 1.  Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine.

Authors:  Anne Luise Haulund Vollesen; Faisal Mohammad Amin; Messoud Ashina
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 2.  Neurogenic inflammation and migraine: implications for the therapeutics.

Authors:  Stephen J Peroutka
Journal:  Mol Interv       Date:  2005-10

3.  Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat.

Authors:  P R Holland; S Akerman; P J Goadsby
Journal:  Eur J Neurosci       Date:  2006-11       Impact factor: 3.386

Review 4.  Cluster headache, hypothalamus, and orexin.

Authors:  Philip R Holland; Peter J Goadsby
Journal:  Curr Pain Headache Rep       Date:  2009-04

Review 5.  Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.

Authors:  David Dodick; Richard B Lipton; Vincent Martin; Vasilios Papademetriou; Wayne Rosamond; Antoinette MaassenVanDenBrink; Hassan Loutfi; K Michael Welch; Peter J Goadsby; Steven Hahn; Susan Hutchinson; David Matchar; Stephen Silberstein; Timothy R Smith; R Allan Purdy; Jane Saiers
Journal:  Headache       Date:  2004-05       Impact factor: 5.887

6.  Acid-sensing ion channel 1: a novel therapeutic target for migraine with aura.

Authors:  Philip R Holland; Simon Akerman; Anna P Andreou; Nazia Karsan; John A Wemmie; Peter J Goadsby
Journal:  Ann Neurol       Date:  2012-10       Impact factor: 10.422

7.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

8.  Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system.

Authors:  P J Goadsby; L Edvinsson; R Ekman
Journal:  Ann Neurol       Date:  1988-02       Impact factor: 10.422

9.  Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input.

Authors:  P J Goadsby; J D Classey
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

Review 10.  Targeted Orexin and Hypothalamic Neuropeptides for Migraine.

Authors:  Lauren C Strother; Anan Srikiatkhachorn; Weera Supronsinchai
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620
View more
  3 in total

1.  Hejie Zhitong prescription promotes sleep and inhibits nociceptive transmission-associated neurotransmitter activity in a rodent migraine model.

Authors:  Xinna Wang; Hongfei Zhao; Liming Liu; Ping Niu; Chao Zhai; Jinjian Li; Qiaoli Xu; Dexi Zhao
Journal:  Chin Med       Date:  2020-09-29       Impact factor: 5.455

Review 2.  Lasmiditan mechanism of action - review of a selective 5-HT1F agonist.

Authors:  David B Clemow; Kirk W Johnson; Helen M Hochstetler; Michael H Ossipov; Ann M Hake; Andrew M Blumenfeld
Journal:  J Headache Pain       Date:  2020-06-10       Impact factor: 7.277

3.  The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study.

Authors:  Stephen D Silberstein; Joshua M Cohen; Michael J Seminerio; Ronghua Yang; Sait Ashina; Zaza Katsarava
Journal:  J Headache Pain       Date:  2020-09-21       Impact factor: 7.277
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.